Transgenic Plasmodium that expresses HIV-1 Gag elicits immunity and protects mice against vaccinia virus-gag and malarial parasites

Vaccine

Volumn 28, Issue 50, 2010, Pages 7915-7922

  Jiang, Bo ^a   Qin, Li ^a   Du, Yanhua ^b   Peng, Nanzheng ^a   Chen, Ling ^a   Chen, Zhiwei ^b   Chen, Xiaoping ^a  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

HIV 1; Transgenic Plasmodium berghei; Vaccine

Indexed keywords

GAG PROTEIN; PBGAG VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNITY; MOUSE; NONHUMAN; PLASMODIUM; PLASMODIUM BERGHEI; PLASMODIUM YOELII; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINIA VIRUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, PROTOZOAN; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV-1; INTERFERON-GAMMA; MALARIA; MALARIA VACCINES; MICE; MICE, INBRED BALB C; ORGANISMS, GENETICALLY MODIFIED; OVARY; PLASMODIUM BERGHEI; PLASMODIUM YOELII; SPLEEN; TRANSFECTION; VACCINIA;

EID: 78650255639     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.075     Document Type: Article

References (35)

1. Meyers A., Chakauya E., Shephard E., Tanzer F.L., Maclean J., Lynch A., et al. Expression of HIV-1 antigens in plants as potential subunit vaccines. BMC Biotechnol 2008, 8:53.
2. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.-Y., Roopchand V., et al. Effect of plasmid dna vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007, 81(10):5257-5269.
3. Greenwood B., Fidock D., Kyle D., Kappe S., Alonso P., Collins F., et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008, 118(4):1266-1276.
4. Pombo D.J., Lawrence G., Hirunpetcharat C., Rzepczyk C., Bryden M., Cloonan N., et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002, 360(9333):610-617.
5. Ting L.M., Gissot M., Coppi A., Sinnis P., Kim K. Attenuated Plasmodium yoelii lacking purine nucleoside phosphorylase confer protective immunity. Nat Med 2008, 14(9):954-958.
6. Dorrell L., Yang H., Ondondo B., Dong T., di Gleria K., Suttill A., et al. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency Virus Type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag Vaccine. J Virol 2006, 80(10):4705-4716.
7. Lorin C., Mollet L., Delebecque F., Combredet C., Hurtrel B., Charneau P., et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) Type 1 Clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 2004, 78(1):146-157.
8. Cooper D., Wright K.J., Calderon P.C., Guo M., Nasar F., Johnson J.E., et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus Type 1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 2008, 82(1):207-219.
9. Santos K., Duke C.M., Rodriguez-Colon S.M., Dakwar A., Fan S., Keefer M.C., et al. Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. Vaccine 2007, 25(9):1634-1646.
10. Schnell M.J., Foley H.D., Siler C.A., McGettigan J.P., Dietzschold B., Pomerantz R.J. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc Natl Acad Sci USA 2000, 97(7):3544-3549.
11. Xin K.Q., Sekimoto Y., Takahashi T., Mizuguchi H., Ichino M., Yoshida A., et al. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV. Vaccine 2007, 25(19):3809-3815.
12. Yu S., Feng X., Shu T., Matano T., Hasegawa M., Wang X., et al. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine 2008, 26(48):6124-6131.
13. Lin J., Zhi Y., Mays L., Wilson J.M. Vaccines based on novel Adeno-associated virus vectors elicit aberrant CD8+ T-Cell Responses in Mice. J Virol 2007, 81(21):11840-11849.
14. Kanekiyo M., Matsuo K., Hamatake M., Hamano T., Ohsu T., Matsumoto S., et al. Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant mycobacterium bovis bacille calmette-guerin expressing human immunodeficiency Virus Type 1 Gag. J Virol 2005, 79(14):8716-8723.
15. Xin K.-Q., Hoshino Y., Toda Y., Igimi S., Kojima Y., Jounai N., et al. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 2003, 102(1):223-228.
16. Paterson Y., Johnson R. Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens. Expert Rev Vaccines 2004, 3(4):119-134.
17. Tsunetsugu-Yokota Y., Ishige M., Murakami M. Oral attenuated Salmonella enterica serovar Typhimurium vaccine expressing codon-optimized HIV type 1 Gag enhanced intestinal immunity in mice. AIDS Res Hum Retroviruses 2007, 23(2):278-286.
18. Breton M., Zhao C., Ouellette M., Tremblay M.J., Papadopoulou B. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. J Gen Virol 2007, 88(1):217-225.
19. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13(1):46-53.
20. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457(7225):87-91.
21. Stevenson M.M., Riley E.M. Innate immunity to malaria. Nat Rev Immunol 2004, 4(3):169-180.
22. Ing R., Segura M., Thawani N., Tam M., Stevenson M.M. Interaction of mouse dendritic cells and malaria-infected erythrocytes: uptake, maturation, and antigen presentation. J Immunol 2006, 176(1):441-450.
23. Janse C.J., Ramesar J., Waters A.P. High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite Plasmodium berghei. Nat Protoc 2006, 1(1):346-356.
24. Margos G., van Dijk M.R., Ramesar J., Janse C.J., Waters A.P., Sinden R.E. Transgenic expression of a mosquito-stage malarial protein, Pbs21, in blood stages of transformed Plasmodium berghei and induction of an immune response upon infection. Infect Immun 1998, 66(8):3884-3891.
25. Huang X., Lu B., Yu W., Fang Q., Liu L., Zhuang K., et al. A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One 2009, 4(1):e4180.
26. Kocken C.H.M., van der Wel A.M., Dubbeld M.A., Narum D.L., van de Rijke F.M., van Gemert G.-J., et al. Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization. J Biol Chem 1998, 273(24):15119-15124.
27. Qiu J.T., Chang T.C., Lin C.T., Chen Y.M., Li F.Q., Soong Y.K., et al. Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag. Vaccine 2007, 25(2):253-263.
28. Parroche P., Lauw F.N., Goutagny N., Latz E., Monks B.G., Visintin A., et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA 2007, 104(6):1919-1924.
29. Jones T., Obaldia N., Gramzinski R., Hoffman S. Repeated infection of Aotus monkeys with Plasmodium falciparum induces protection against subsequent challenge with homologous and heterologous strains of parasite. Am J Trop Med Hyg 2000, 62(6):675-680.
30. Tetsutani K., To H., Torii M., Hisaeda H., Himeno K. Malaria parasite induces tryptophan-related immune suppression in mice. Parasitology 2007, 134(Pt 7):923-930.
31. Granucci F., Feau S., Zanoni I., Pavelka N., Vizzardelli C., Raimondi G., et al. The immune response is initiated by dendritic cells via interaction with microorganisms and interleukin-2 production. J Infect Dis 2003, 187(Suppl. 2):S346-S350.
32. Melief C. Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?. Eur J Immunol 2003, 33(10):2645-2654.
33. Skinner-Adams T.S., McCarthy J.S., Gardiner D.L., Andrews K.T. HIV and malaria co-infection: interactions and consequences of chemotherapy. Trends Parasitol 2008, 24(6):264-271.
34. Kalyesubula I., Musoke-Mudido P., Marum L., Bagenda D., Aceng E., Ndugwa C., et al. Effects of malaria infection in human immunodeficiency virus type 1-infected Ugandan children. Pediatr Infect Dis J 1997, 16(9):876-881.
35. Kublin J.G., Patnaik P., Jere C.S., Miller W.C., Hoffman I.F., Chimbiya N., et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005, 365(9455):233-240.